Comment on CMS-2026-2081-0001
AbbVie IncSupportBusiness
Summary: AbbVie Inc., a large biopharmaceutical company, supports the review of Essential Health Benefits (EHB) and urges HHS to expand prescription drug coverage. They specifically advocate for closing regulatory gaps that allow plans to use "copay maximizers" and "alternative funding programs" to shift costs to patients, and they call for a robust federal floor for drug coverage.
AbbVie appreciates the opportunity to comment on this RFI regarding the comprehensive review of EHB standards, and would welcome the opportunity to serve as a resource to the Department as it finalizes this rule. Our detailed comments are attached.